Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer

Simona Cima, Anna Myriam Perrone, Paolo Castellucci, Gabriella Macchia, Milly Buwenge, Silvia Cammelli, Savino Cilla, Martina Ferioli, Gabriella Ferrandina, Andrea Galuppi, Eugenio Salizzoni, Daniela Rubino, Stefano Fanti, Pierandrea De Iaco, Alessio Giuseppe Morganti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The aim of this study was to investigate the impact of SUVmax fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) measured in the primary tumor, pelvic and para-aortic node with disease-free survival (DFS) and overall survival (OS) in patients with locally advanced cervical cancer. Methods and Materials: A total of 92 patients with histological diagnosis of locally advanced cervical cancer are treated with radiochemotherapy plus brachytherapy boost from January 2008 to April 2014 in our Institution. A pretreatment FDG-PET/CT for staging and radiotherapy planning was performed, and the value of SUVmax measured in primary tumor and positive nodes was related to DFS and OS. Results: Univariate analysis showed that DFS is related to FDG-PET/CT positive para-aortic nodes (P = 0.01), International Federation of Gynecology and Obstetrics (FIGO) stage of disease (P = 0.01), and primary tumor SUVmax (P = 0.02), and OS is related to positive para-aortic nodes (P = 0.01) and primary tumor SUVmax (P = 0.02). In multivariate analysis, DFS is modified by FDG-PET/CT positive para-aortic lymph nodes, stage and high T SUVmax (P = 0.02; P = 0.003; P = 0.04), but the only worse prognostic factor of OS is the high SUVmax in the primary tumor (P = 0.01). Conclusions: We found that T SUVmax, stage, and para-aortic lymph node status assessed by FDG-PET were independent prognostic factors of DFS, whereas only T SUVmax correlated with OS.

Original languageEnglish
Pages (from-to)575-580
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume28
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Uterine Cervical Neoplasms
Disease-Free Survival
Survival
Neoplasms
Lymph Nodes
Brachytherapy
Chemoradiotherapy
Gynecology
Obstetrics
Radiotherapy
Multivariate Analysis
Positron Emission Tomography Computed Tomography

Keywords

  • F-FDG-PET/CT
  • Cervix cancer
  • Chemotherapy
  • Prognostic factor
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer. / Cima, Simona; Perrone, Anna Myriam; Castellucci, Paolo; Macchia, Gabriella; Buwenge, Milly; Cammelli, Silvia; Cilla, Savino; Ferioli, Martina; Ferrandina, Gabriella; Galuppi, Andrea; Salizzoni, Eugenio; Rubino, Daniela; Fanti, Stefano; De Iaco, Pierandrea; Morganti, Alessio Giuseppe.

In: International Journal of Gynecological Cancer, Vol. 28, No. 3, 01.03.2018, p. 575-580.

Research output: Contribution to journalArticle

Cima, S, Perrone, AM, Castellucci, P, Macchia, G, Buwenge, M, Cammelli, S, Cilla, S, Ferioli, M, Ferrandina, G, Galuppi, A, Salizzoni, E, Rubino, D, Fanti, S, De Iaco, P & Morganti, AG 2018, 'Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer', International Journal of Gynecological Cancer, vol. 28, no. 3, pp. 575-580. https://doi.org/10.1097/IGC.0000000000001207
Cima, Simona ; Perrone, Anna Myriam ; Castellucci, Paolo ; Macchia, Gabriella ; Buwenge, Milly ; Cammelli, Silvia ; Cilla, Savino ; Ferioli, Martina ; Ferrandina, Gabriella ; Galuppi, Andrea ; Salizzoni, Eugenio ; Rubino, Daniela ; Fanti, Stefano ; De Iaco, Pierandrea ; Morganti, Alessio Giuseppe. / Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer. In: International Journal of Gynecological Cancer. 2018 ; Vol. 28, No. 3. pp. 575-580.
@article{34658052888a4bc686baf6e20440b8d5,
title = "Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer",
abstract = "Objective: The aim of this study was to investigate the impact of SUVmax fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) measured in the primary tumor, pelvic and para-aortic node with disease-free survival (DFS) and overall survival (OS) in patients with locally advanced cervical cancer. Methods and Materials: A total of 92 patients with histological diagnosis of locally advanced cervical cancer are treated with radiochemotherapy plus brachytherapy boost from January 2008 to April 2014 in our Institution. A pretreatment FDG-PET/CT for staging and radiotherapy planning was performed, and the value of SUVmax measured in primary tumor and positive nodes was related to DFS and OS. Results: Univariate analysis showed that DFS is related to FDG-PET/CT positive para-aortic nodes (P = 0.01), International Federation of Gynecology and Obstetrics (FIGO) stage of disease (P = 0.01), and primary tumor SUVmax (P = 0.02), and OS is related to positive para-aortic nodes (P = 0.01) and primary tumor SUVmax (P = 0.02). In multivariate analysis, DFS is modified by FDG-PET/CT positive para-aortic lymph nodes, stage and high T SUVmax (P = 0.02; P = 0.003; P = 0.04), but the only worse prognostic factor of OS is the high SUVmax in the primary tumor (P = 0.01). Conclusions: We found that T SUVmax, stage, and para-aortic lymph node status assessed by FDG-PET were independent prognostic factors of DFS, whereas only T SUVmax correlated with OS.",
keywords = "F-FDG-PET/CT, Cervix cancer, Chemotherapy, Prognostic factor, Radiotherapy",
author = "Simona Cima and Perrone, {Anna Myriam} and Paolo Castellucci and Gabriella Macchia and Milly Buwenge and Silvia Cammelli and Savino Cilla and Martina Ferioli and Gabriella Ferrandina and Andrea Galuppi and Eugenio Salizzoni and Daniela Rubino and Stefano Fanti and {De Iaco}, Pierandrea and Morganti, {Alessio Giuseppe}",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/IGC.0000000000001207",
language = "English",
volume = "28",
pages = "575--580",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer

AU - Cima, Simona

AU - Perrone, Anna Myriam

AU - Castellucci, Paolo

AU - Macchia, Gabriella

AU - Buwenge, Milly

AU - Cammelli, Silvia

AU - Cilla, Savino

AU - Ferioli, Martina

AU - Ferrandina, Gabriella

AU - Galuppi, Andrea

AU - Salizzoni, Eugenio

AU - Rubino, Daniela

AU - Fanti, Stefano

AU - De Iaco, Pierandrea

AU - Morganti, Alessio Giuseppe

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: The aim of this study was to investigate the impact of SUVmax fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) measured in the primary tumor, pelvic and para-aortic node with disease-free survival (DFS) and overall survival (OS) in patients with locally advanced cervical cancer. Methods and Materials: A total of 92 patients with histological diagnosis of locally advanced cervical cancer are treated with radiochemotherapy plus brachytherapy boost from January 2008 to April 2014 in our Institution. A pretreatment FDG-PET/CT for staging and radiotherapy planning was performed, and the value of SUVmax measured in primary tumor and positive nodes was related to DFS and OS. Results: Univariate analysis showed that DFS is related to FDG-PET/CT positive para-aortic nodes (P = 0.01), International Federation of Gynecology and Obstetrics (FIGO) stage of disease (P = 0.01), and primary tumor SUVmax (P = 0.02), and OS is related to positive para-aortic nodes (P = 0.01) and primary tumor SUVmax (P = 0.02). In multivariate analysis, DFS is modified by FDG-PET/CT positive para-aortic lymph nodes, stage and high T SUVmax (P = 0.02; P = 0.003; P = 0.04), but the only worse prognostic factor of OS is the high SUVmax in the primary tumor (P = 0.01). Conclusions: We found that T SUVmax, stage, and para-aortic lymph node status assessed by FDG-PET were independent prognostic factors of DFS, whereas only T SUVmax correlated with OS.

AB - Objective: The aim of this study was to investigate the impact of SUVmax fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) measured in the primary tumor, pelvic and para-aortic node with disease-free survival (DFS) and overall survival (OS) in patients with locally advanced cervical cancer. Methods and Materials: A total of 92 patients with histological diagnosis of locally advanced cervical cancer are treated with radiochemotherapy plus brachytherapy boost from January 2008 to April 2014 in our Institution. A pretreatment FDG-PET/CT for staging and radiotherapy planning was performed, and the value of SUVmax measured in primary tumor and positive nodes was related to DFS and OS. Results: Univariate analysis showed that DFS is related to FDG-PET/CT positive para-aortic nodes (P = 0.01), International Federation of Gynecology and Obstetrics (FIGO) stage of disease (P = 0.01), and primary tumor SUVmax (P = 0.02), and OS is related to positive para-aortic nodes (P = 0.01) and primary tumor SUVmax (P = 0.02). In multivariate analysis, DFS is modified by FDG-PET/CT positive para-aortic lymph nodes, stage and high T SUVmax (P = 0.02; P = 0.003; P = 0.04), but the only worse prognostic factor of OS is the high SUVmax in the primary tumor (P = 0.01). Conclusions: We found that T SUVmax, stage, and para-aortic lymph node status assessed by FDG-PET were independent prognostic factors of DFS, whereas only T SUVmax correlated with OS.

KW - F-FDG-PET/CT

KW - Cervix cancer

KW - Chemotherapy

KW - Prognostic factor

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85042852771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042852771&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000001207

DO - 10.1097/IGC.0000000000001207

M3 - Article

C2 - 29372911

AN - SCOPUS:85042852771

VL - 28

SP - 575

EP - 580

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 3

ER -